Cargando…

Biomarkers in melanoma

Biomarkers are tumour- or host-related factors that correlate with tumour biological behaviour and patient prognosis. High-throughput analytical techniques—DNA and RNA microarrays—have identified numerous possible biomarkers, but their relevance to melanoma progression, clinical outcome and the sele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gogas, H., Eggermont, A. M. M., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2009
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712589/ https://www.ncbi.nlm.nih.gov/pubmed/19617299 http://dx.doi.org/10.1093/annonc/mdp251

Ejemplares similares

Utility of adjuvant systemic therapy in melanoma
por: Eggermont, A. M. M., et al.
Publicado: (2009)

Staging of cutaneous melanoma
por: Mohr, P., et al.
Publicado: (2009)

Small molecules and targeted therapies in distant metastatic disease
por: Hersey, P., et al.
Publicado: (2009)

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014)

Immunotherapy of distant metastatic disease
por: Schadendorf, D., et al.
Publicado: (2009)

Epidemiology of invasive cutaneous melanoma
por: MacKie, R. M., et al.
Publicado: (2009)

Surgery and radiotherapy in the treatment of cutaneous melanoma
por: Testori, A., et al.
Publicado: (2009)

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
por: Bouwhuis, Marna G., et al.
Publicado: (2009)

Blocking factors against leucocyte-dependent melanoma antibody in the sera of melanoma patients.
por: Murray, E., et al.
Publicado: (1977)

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma
por: van Herpen, Carla M.L., et al.
Publicado: (2019)

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
por: Guo, J., et al.
Publicado: (2017)

Low natural-killer-cell activity in familial melanoma patients and their relatives.
por: Hersey, P., et al.
Publicado: (1979)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
por: Hauschild, A, et al.
Publicado: (2001)

Reply: Value of tyrosinase RT–PCR in melanoma prognosis
por: Gogas, H
Publicado: (2003)

Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety
por: Malvehy, J, et al.
Publicado: (2014)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
por: Long, G. V., et al.
Publicado: (2017)

Adjuvant therapy for high-risk melanoma
por: Eggermont, Alexander M.M.
Publicado: (2013)

What is changing in the adjuvant treatment of melanoma?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence
por: Hoefsmit, Esmee P., et al.
Publicado: (2023)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
por: Long, G V, et al.
Publicado: (2019)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

Detection of carcinoembryonic-like antigen on melanoma cells by leucocyte-dependent-antibody assays.
por: Morgan, G., et al.
Publicado: (1977)

Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon
por: Gogas, H, et al.
Publicado: (2002)

Surgical management of melanoma: an EORTC Melanoma Group survey
por: Testori, A, et al.
Publicado: (2013)

Societal preference values for advanced melanoma health states in the United Kingdom and Australia
por: Beusterien, K M, et al.
Publicado: (2009)

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
por: Tawbi, Hussein A, et al.
Publicado: (2022)

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
por: Garbe, Claus, et al.
Publicado: (2020)

Lack of clinical efficacy of imatinib in metastatic melanoma
por: Ugurel, S, et al.
Publicado: (2005)

The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia.
por: Bataille, V., et al.
Publicado: (1998)

Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance
por: Lage, H, et al.
Publicado: (2000)

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

What can we learn from phase II adjuvant trials in melanoma?
por: Keilholz, U, et al.
Publicado: (2000)

Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications
por: Welker, P, et al.
Publicado: (2000)

Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
por: Pham, James P., et al.
Publicado: (2023)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1nc7c75ip58sveek9am0kv5flc